ABSTRACT
Human immunodeficiency syndrome (HIV) whose full-blown period is called acquired immunity deficiency syndrome (AIDS) is today a terminal disease. While one weakens the body hormones; the other comes to claim the life with its accompanying opportunistic diseases. Several factors have been reviewed to be causing the infection and its prevalence as well as its socio-economic; scientific and cultural dimensions. The cost implication of this ailment is enormous when considered from individual; national or global perspective; especially when the cost of treatment and the cost of the disability adjusted life years (DALYs) lost to incapacitation from HIV/AIDS is considered. This study has investigated the financial implications of treatment and the DALYs lost to HIV/AIDS from the perspective of sub-Saharan Africa covering thirty-five countries. Infected population of age 15-49 years were considered; being the active life year age group. Applying Morrow's DALYs measurement; and Ainsworth's per capita general rule method of costing HIV/AIDS; it was found that the cost of treatment of HIV/AIDS in any country depends on her economic strength on the one hand and the size of the infected population on the other; to the extent that no country spends or loses less than 3 percent of her national income on treatment and to DALYs. To any country; the financial cost of the DALYs lost to HIV/AIDS is much more than the cost of treatment per episode; mostly huge enough to develop a sector of the country's economy. However; a single recommendation could be difficult as individual countries experience different effect; but different countries must pursue long-run anti-prevalence policies individually and as economic region or bloc